FDA warning dyslipidemia weight gain

FDA Adds Metabolic Warnings to Fanapt

Psychiatric News Alert | February 16, 2012

The U.S. Food and Drug Administration has enacted a major change to the "Warnings and Precautions" portion of the prescribing information for the atypical antipsychotic Fanapt (iloperidone). The label now includes information about the metabolic changes associated with atypical antipsychotic drugs that may increase cardiovascular and cerebrovascular risk. These changes include hyperglycemia, dyslipidemia, and weight gain. The revised label is posted at http://www.pharma.us.novartis.com/product/pi/pdf/fanapt.pdf. Fanapt was approved by the FDA in 2009 for the treatment of schizophrenia after initially being turned down. Read more about it in Psychiatric News here .

(Image: Sebastian Kaulitzki/Shutterstock)

Keep reading

ADHD depression anxiety

Early Puberty Linked to Increased Risk of Mental Illness

anxiety Healthy Minds APA poll

FDA Adds Metabolic Warnings to Fanapt

Share this post

Keep reading

Early Puberty Linked to Increased Risk of Mental Illness

Psych News Alert: Climate Change Significantly Affects Mental Health, Especially Among Younger Adults